List of Excipients in Branded Drug COBENFY

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
ER Squibb & Sons LLC	COBENFY	xanomeline and trospium chloride	0003-0050	ASCORBIC ACID	2039-10-29
ER Squibb & Sons LLC	COBENFY	xanomeline and trospium chloride	0003-0050	CELLULOSE, MICROCRYSTALLINE	2039-10-29
ER Squibb & Sons LLC	COBENFY	xanomeline and trospium chloride	0003-0050	FERRIC OXIDE RED	2039-10-29
ER Squibb & Sons LLC	COBENFY	xanomeline and trospium chloride	0003-0050	FERRIC OXIDE YELLOW	2039-10-29
ER Squibb & Sons LLC	COBENFY	xanomeline and trospium chloride	0003-0050	HYPROMELLOSE	2039-10-29
ER Squibb & Sons LLC	COBENFY	xanomeline and trospium chloride	0003-0050	LACTOSE MONOHYDRATE	2039-10-29
ER Squibb & Sons LLC	COBENFY	xanomeline and trospium chloride	0003-0050	TALC	2039-10-29

COBENFY Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Cobenfy, Bristol Myers Squibb's oral combination of xanomeline and trospium chloride, was approved by the FDA on Sept. 26, 2024, for schizophrenia in adults. Its formulation uses conventional capsule excipients, but the product's commercial opportunity lies in improving tolerability, dose flexibility, manufacturing robustness, and adherence without changing the approved pharmacology. Excipient suppliers and formulation partners have the strongest opportunities in next-generation capsules, modified-release systems, orally disintegrating formats, and patient-specific dosage presentations.[1]

What is Cobenfy and why does its excipient strategy matter?

Cobenfy combines xanomeline, a muscarinic receptor agonist, with trospium chloride, a peripherally restricted muscarinic antagonist. The combination is designed to preserve central muscarinic activity while reducing peripheral cholinergic adverse effects associated with xanomeline alone.[1,2]

The approved product is administered orally twice daily on an empty stomach. Available strengths are:

Cobenfy strength	Xanomeline	Trospium chloride
50 mg/20 mg	50 mg	20 mg
100 mg/20 mg	100 mg	20 mg
125 mg/30 mg	125 mg	30 mg

The FDA label instructs patients to take Cobenfy at least one hour before food or two hours after food. Food reduces exposure to both active components, making disintegration, dissolution, gastric emptying, and food-effect control commercially important formulation variables.[1]

The current dosage form is a hard capsule containing conventional pharmaceutical excipients. The label identifies excipients including microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, hypromellose, sodium lauryl sulfate, talc, titanium dioxide, and capsule-shell materials.[1]

What excipients are used in the approved Cobenfy capsules?

The current excipient architecture is consistent with an immediate-release solid oral product:

Excipient function	Likely role in Cobenfy
Microcrystalline cellulose	Diluent and capsule fill support
Croscarmellose sodium	Superdisintegrant
Colloidal silicon dioxide	Glidant and flow aid
Magnesium stearate	Lubricant
Sodium lauryl sulfate	Wetting and dissolution aid
Hypromellose	Capsule-shell or coating material
Talc and titanium dioxide	Opacifying, processing, or shell-color functions
Gelatin or hypromellose shell components	Capsule structure and patient identification

The primary formulation challenge is not simply tablet or capsule manufacture. Cobenfy contains two pharmacologically distinct active ingredients with different dose ratios, exposure characteristics, and tolerability considerations. An excipient system must support content uniformity across three strengths while preserving rapid and reproducible release.

How does food affect Cobenfy formulation opportunities?

Food effect is one of the clearest areas for formulation innovation. Cobenfy must be taken on an empty stomach because food reduces systemic exposure.[1]

That restriction creates commercial opportunities for:

1. Food-effect reduction. A formulation that produces more consistent exposure across fed and fasted states could improve adherence and reduce administration errors.
2. Gastroretentive or controlled-release delivery. A modified-release system could alter the absorption profile, but it would require new clinical pharmacokinetic and safety studies.
3. Delayed-release protection. Enteric or pH-responsive systems could change site-specific release, although they may be difficult to reconcile with the current food-related exposure profile.
4. Dose-timing flexibility. A formulation that permits administration with meals would have a direct commercial advantage in schizophrenia, where adherence and caregiver administration are major operational concerns.
5. Simplified dosing. A once-daily formulation could reduce the current twice-daily burden, but it would need to maintain exposure and tolerability across the full dosing interval.

The most valuable excipient innovation would be an evidence-backed platform that reduces food sensitivity without increasing peak-related adverse effects.

What formulation patents could protect Cobenfy lifecycle extensions?

Formulation patents could protect Cobenfy beyond the core composition and method-of-use estate. The strongest claim categories would include:

Food-effect mitigation

Claims could cover specific ratios of disintegrant, surfactant, filler, and lubricant that produce defined pharmacokinetic profiles under fed and fasted conditions.

Dual-active uniformity

Cobenfy has a fixed combination of xanomeline and trospium chloride. A patent could claim a capsule-fill composition that maintains content uniformity, dissolution, and stability for both active ingredients across all marketed strengths.

Modified-release dosage forms

Potential claims could cover:

• Extended-release xanomeline with immediate-release trospium
• Immediate-release xanomeline with delayed-release trospium
• Biphasic release profiles
• Multiparticulate pellets or minitablets
• Enteric-coated beads
• Osmotic or gastroretentive systems

The commercial logic is strongest where one component requires a different release profile from the other. A technically credible combination product would need to demonstrate that modified release does not reduce central efficacy or compromise the peripheral tolerability rationale.

Abuse-deterrent and handling properties

Although Cobenfy is not an opioid and does not carry an opioid abuse-deterrence requirement, tamper-resistant or abuse-limiting capsule technologies could support institutional use and supply-chain controls. This is a secondary opportunity, not the central lifecycle strategy.

Pediatric and geriatric formulations

Age-specific formulations could include:

• Sprinkle capsules
• Oral granules
• Powder for suspension
• Orally disintegrating tablets
• Liquid suspensions
• Lower-dose capsule strengths

A pediatric indication would require separate clinical and regulatory development. The current FDA approval is for adults.

Stability and manufacturing patents

Patents could cover:

• Low-moisture capsule-fill systems
• Moisture-barrier packaging
• Defined particle-size distributions
• Controlled milling or blending processes
• Excipient-specific stabilization systems
• Low-shear lubrication methods
• Continuous manufacturing processes

These claims can create manufacturing barriers even when the active-ingredient composition is no longer strongly protected.

How strong is the Cobenfy formulation patent opportunity?

The formulation opportunity is commercially meaningful but technically constrained. A formulation patent is strongest when it solves a clinically measurable problem, such as food sensitivity, dosing frequency, gastrointestinal tolerability, or capsule administration.

A patent based only on substituting one conventional filler for another would face a higher obviousness risk. A more defensible patent would connect the excipient combination to unexpected results, including:

• Reduced fed-state variability
• Improved dissolution at multiple pH levels
• Lower degradation of xanomeline
• Improved trospium release consistency
• Lower capsule weight or smaller capsule size
• Better stability under accelerated conditions
• Demonstrated bioequivalence or superior adherence

The patent owner would also need to distinguish formulation claims from broad combination-product claims and method-of-use claims. Broad claims covering xanomeline plus trospium may remain the principal exclusivity layer, while excipient claims would provide secondary protection and product differentiation.

What is the FDA regulatory status of Cobenfy?

Cobenfy is an FDA-approved small-molecule combination product. It is not a biologic and does not create biosimilar exclusivity.

Regulatory item	Status
FDA approval	Sept. 26, 2024
Indication	Schizophrenia in adults
Dosage form	Oral capsules
Administration	Twice daily, on an empty stomach
Active ingredients	Xanomeline and trospium chloride
Regulatory pathway	New drug application
Biosimilar pathway	Not applicable
Generic pathway	Abbreviated new drug application, subject to applicable exclusivity and patent barriers
Orange Book relevance	Applicable because Cobenfy is an approved small-molecule drug

FDA approval was based primarily on the EMERGENT clinical development program, including randomized trials evaluating Cobenfy in adults with schizophrenia.[1,3]

When does Cobenfy lose exclusivity?

Cobenfy's commercial exclusivity will depend on several separate dates:

• FDA new chemical entity exclusivity, if granted
• Any applicable fixed-combination or clinical-investigation exclusivity
• Listed Orange Book patents
• Pediatric exclusivity, if later awarded
• Patent-term adjustments or extensions
• Litigation settlements with generic applicants

The FDA grants five years of new chemical entity exclusivity when a drug contains an active moiety that has not previously been approved. The regulatory status of xanomeline and trospium must be evaluated at the active-moiety level, and the fixed combination may have additional exclusivity issues depending on the FDA's listing decisions.

Patent expiration cannot be inferred from the FDA approval date. The relevant analysis requires review of the Orange Book, issued patent records, patent-term calculations, terminal disclaimers, and any patent litigation or settlement agreements.[4,5]

What generic entry risks exist for Cobenfy?

Cobenfy has conventional generic-entry exposure because it is an oral small-molecule capsule. A future ANDA applicant could pursue:

• A generic equivalent of all three strengths
• A strength-specific product
• A capsule with different inactive ingredients
• A product challenging listed patents through Paragraph IV certification
• A product waiting for relevant regulatory exclusivity to expire

The highest-risk generic strategy would likely target the immediate-release capsule. A generic applicant would not generally need to reproduce every excipient, but it would need to demonstrate pharmaceutical equivalence and bioequivalence under FDA requirements.

Paragraph IV challenges

Paragraph IV risk will depend on which patents Bristol Myers Squibb lists in the Orange Book. Potentially relevant patent categories include:

• Xanomeline-trospium combinations
• Dosage ratios
• Treatment of schizophrenia
• Dosing schedules
• Specific formulations
• Manufacturing methods

A Paragraph IV notice could trigger Hatch-Waxman litigation and a 30-month stay of approval, subject to statutory conditions and court developments.[5]

Generic launch scenarios

Scenario	Commercial effect
No early challenge	Cobenfy retains market exclusivity until regulatory and patent barriers expire
Paragraph IV filing with litigation	Generic approval may be delayed by the 30-month stay or court outcome
At-risk launch	Generic enters before final patent resolution, creating damages and injunction exposure
Settlement with licensed entry	Entry occurs on an agreed date, potentially with a limited license
Authorized generic	Brand owner or licensee competes with independent ANDA products

Because Cobenfy is a fixed combination, generic applicants may face more complex bioequivalence and analytical requirements than applicants for a single-ingredient capsule.

Which companies are commercial competitors to Cobenfy?

Cobenfy competes with established antipsychotics rather than with a direct generic equivalent in the initial market. Relevant alternatives include:

• Risperidone
• Olanzapine
• Quetiapine
• Aripiprazole
• Lurasidone
• Cariprazine
• Clozapine
• Long-acting injectable antipsychotics

The commercial differentiation is based on a non-dopaminergic mechanism and the potential to avoid some adverse effects associated with dopamine D2 receptor blockade. Cobenfy still carries important warnings and tolerability considerations, including gastrointestinal effects, urinary retention, increased heart rate, reduced gastric motility, and risks associated with muscarinic activity.[1]

The main competitive risk is not a competing excipient. It is the ability of established antipsychotics to retain prescribing share through low cost, generic availability, long-acting injectable options, and extensive physician familiarity.

What excipient suppliers and CDMOs could gain from Cobenfy?

Commercial opportunities extend beyond the branded product.

Excipient suppliers

Suppliers may target:

• Low-peroxide microcrystalline cellulose
• High-functionality croscarmellose
• Direct-compression grades
• Low-moisture capsule excipients
• Surfactants that improve wetting without increasing degradation
• Lubricants optimized for blend uniformity
• Hypromellose capsule shells
• Moisture-barrier and light-protective packaging

The most valuable supplier position would be a qualified excipient with documented performance in dissolution, content uniformity, and stability for the xanomeline-trospium combination.

Contract development and manufacturing organizations

CDMOs could offer:

• Scale-up of multi-strength capsule fills
• Process analytical technology for blend uniformity
• Multiparticulate development
• Modified-release prototypes
• Bioequivalence manufacturing for generic applicants
• Stability and packaging programs
• Global registration batches

Cobenfy's three strengths make process control commercially relevant. A CDMO that can reduce changeover time and maintain blend uniformity across strength changes could compete for lifecycle, generic, and international manufacturing work.

How does Cobenfy compare with other CNS formulation opportunities?

Attribute	Cobenfy	Traditional oral antipsychotic	Long-acting injectable
Administration	Twice-daily capsule	Often once daily	Monthly or longer
Food restriction	Yes	Product-dependent	Generally no oral food effect
Excipient opportunity	High for food effect and adherence	Moderate	High for depot and injection systems
Generic risk	Expected over time	Often mature	More complex
Biosimilar risk	None	None	None for small-molecule injectables
Lifecycle opportunity	Modified release, sprinkle, ODT, pediatric	New formulations and combinations	Longer-interval injectables

Cobenfy has a stronger oral lifecycle opportunity than many mature antipsychotics because the current product carries a food restriction and twice-daily schedule. Those limitations create measurable targets for formulation development.

What patent litigation and licensing issues affect Cobenfy?

Bristol Myers Squibb acquired Karuna Therapeutics in 2024 for approximately $14 billion, bringing Karuna's xanomeline-trospium program into BMS's portfolio.[6] The transaction consolidated commercial rights and development control under BMS.

Future commercial agreements may involve:

• Regional commercialization licenses
• Manufacturing licenses
• Excipient or delivery-platform licenses
• Generic settlement agreements
• Authorized-generic arrangements
• Formulation-development collaborations

No biosimilar litigation is relevant because Cobenfy is a small-molecule drug. The most important legal risks are Orange Book patent challenges, formulation patent validity, obviousness attacks, written-description issues, and claim-scope disputes over combination dosage forms.

Key Takeaways

• Cobenfy is a twice-daily xanomeline and trospium chloride capsule approved for adult schizophrenia.
• Its empty-stomach administration creates the clearest formulation opportunity.
• The current product uses standard immediate-release excipients, including microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, and sodium lauryl sulfate.
• High-value excipient innovation would reduce food-effect variability, improve tolerability, simplify dosing, or support alternative dosage forms.
• Formulation patents are more defensible when linked to unexpected pharmacokinetic, stability, or manufacturing results.
• Generic competition will likely focus on immediate-release capsules and may involve Paragraph IV litigation.
• Biosimilar risk does not apply.
• Excipient suppliers and CDMOs can pursue opportunities in low-moisture materials, modified release, multiparticulates, sprinkle products, and generic bioequivalence manufacturing.
• BMS's acquisition of Karuna consolidated the commercial and intellectual-property position around Cobenfy.

FAQs

Can Cobenfy be reformulated as a once-daily product?

Yes, but a once-daily version would require a new formulation program and clinical pharmacokinetic evidence showing adequate exposure, safety, and efficacy across the dosing interval.

Could a generic Cobenfy use different excipients?

Yes. A generic generally does not need to copy every inactive ingredient, provided it meets FDA requirements for pharmaceutical equivalence, bioequivalence, safety, and quality.

Is an enteric-coated Cobenfy capsule commercially attractive?

Potentially. Enteric coating could alter release location and food sensitivity, but it would need to preserve the pharmacologic relationship between xanomeline and trospium and would require substantial development evidence.

Are Cobenfy excipients likely to be separately patentable?

They may be patentable when a specific excipient combination produces unexpected performance, such as reduced food effect, improved stability, or superior dissolution. Routine excipient substitution is less likely to support durable patent protection.

Does Cobenfy have biosimilar exclusivity?

No. Cobenfy is a small-molecule drug regulated through the NDA and ANDA pathways, not the biologic BLA and biosimilar pathways.

References

1. U.S. Food and Drug Administration. (2024). Cobenfy (xanomeline and trospium chloride) capsules: Prescribing information. https://www.accessdata.fda.gov
2. Karuna Therapeutics, Inc. (2023). KarXT clinical development information. https://www.karunatx.com
3. U.S. Food and Drug Administration. (2024, September 26). FDA approves drug with novel mechanism to treat schizophrenia. https://www.fda.gov
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov
5. U.S. Food and Drug Administration. (2024). ANDA submissions: Refuse-to-receive standards and Paragraph IV certifications. https://www.fda.gov
6. Bristol Myers Squibb. (2024). Bristol Myers Squibb completes acquisition of Karuna Therapeutics. https://news.bms.com